Pollyea Daniel A
Division of Hematology, University of Colorado School of Medicine, 1665 Aurora Court, Aurora, CO, 80045, USA.
Best Pract Res Clin Haematol. 2018 Dec;31(4):391-395. doi: 10.1016/j.beha.2018.09.007. Epub 2018 Sep 20.
There has been little progress in drug development in acute myeloid leukemia (AML) in the recent past. This recently changed with the approval of several therapies for patients with this disease and prompts one to consider which therapies may change practice for patients with AML. To change practice, a therapy must be adopted as a standard of care intervention based on its efficacy and safety profile and must endure as the accepted treatment for a particular indication for a significant period of time. Here I attempt to determine which therapies, approved or in development, may change practice in the field of AML.
近期，急性髓系白血病（AML）的药物研发进展甚微。不过，随着几种针对该疾病患者的疗法获批，这种情况最近有所改变，这促使人们思考哪些疗法可能会改变AML患者的治疗模式。要改变治疗模式，一种疗法必须基于其疗效和安全性概况被采纳为标准治疗干预措施，并且必须在相当长的一段时间内作为特定适应症的公认治疗方法持续存在。在此，我试图确定哪些已获批或正在研发的疗法可能会改变AML领域的治疗模式。
